HistoIndex announces the expansion of its AI-based digital pathology platform towards large-scale NASH preclinical programs for pharmaceutical and biotech companies to achieve quantifiable and reproducible data on therapeutic responses in NASH animal models, and to aid CROs as well as research agencies in validating new models mimicking the NASH disease.
HistoIndex Announces Global Partnerships To Expand AI-Based Digital Pathology Platform As A Drug Discovery Tool In Preclinical Studies For Nonalcoholic Steatohepatitis (NASH) The Singapore-based company has fostered partnerships with pharmaceutical and biotech companies, Contract Research Organizations (CROs), academia and government-linked research institutes in empowering NASH drug discovery. SINGAPORE, Oct. 26, 2019 – HistoIndex announces the …
Singapore HQ
Teletech Park
20 Science Park Road, #01-26/27
Singapore 117674
UK Branch
Queen Elizabeth University Hospital,
Imaging Centre of Excellence, L3-18, Langlands Drive, Glasgow G51 4LB,
United Kingdom
China Subsidiary Office
Room 1001, Building 10
No. 188 Binkang Road, Hangzhou
Zhejiang 310051, China
©2024 Histoindex Pte Ltd. All Rights Reserved. All logos and trademarks are the property of HistoIndex or their respective owners.